Ozempic was Nothing Compared to What’s Next

The Unprepared World: How Incretin Therapies Are Erasing Our Leading Causes of Death

When I started taking a GLP-1 three years ago, my primary goal was straightforward: fix my metabolic health. At the time, my A1C was sitting at a prediabetic 6.6, my weight was 10 pounds heavier, and systemic inflammation was an invisible tax my body paid every single day.

Thirty-six months later, the baseline of my everyday life is unrecognizable. My weight has settled around 200 pounds. My A1C is down to 5.7 and still dropping. Except for minor repetitive stress issues in my wrists from typing, systemic joint and body inflammation has virtually vanished to the point where slipping into the low seat of my Tesla happens with zero pain.

To the individual living it, this feels like an anti-aging miracle. But stepping back to look at the macro picture reveals a far bigger story: we are witnessing the greatest public health transition since the invention of municipal water treatment and modern sewage systems. And yet, society is almost completely unprepared for what happens next.

Eradicating the Causes of Death, Not Biological Time

To understand why this revolution is so misunderstood, we have to separate two concepts that are constantly conflated: slowing the biological clock versus erasing causes of early death.

True biological anti-aging requires manipulating cellular senescence, repairing telomeres, or reprogramming epigenetic code. GLP-1s, dual-agonists (like tirzepatide), and upcoming triple-agonists (like retatrutide) do not rewrite our fundamental cellular decay rate. What they do is act as hyper-effective “morbidity erasers”.

The Morbidity Erasure Model:

In the early 20th century, clean drinking water didn’t make human cells immortal. It simply removed cholera, dysentery, and typhoid allowing millions of people who would have died at 35 to reach their natural potential lifespan of 75.

Incretins are doing the exact same thing for the 21st century’s deadliest non-communicable killers: cardiovascular collapse, fatty liver disease, diabetic renal failure, and peripheral microvascular damage. By removing the primary friction keeping human beings from reaching old age, average life expectancy and more importantly, functional healthspan is about to jump dramatically.

The Domino Effect: From Food Noise to Physical Motion

The true superpower of these medications isn’t just what happens on a molecular level; it is the behavioral cascade they unlock.

For decades, public health policy treated chronic metabolic disease as a moral failure telling people who were carrying 80 pounds of excess fat, bound by joint pain, and trapped in systemic fatigue to “just go to the gym.” The biological friction was simply too high.

When you drop systemic inflammation and normalize blood sugar, the physical barrier to movement collapses. Joints stop aching. Energy restores. The mental food noise driven by hyper-processed diets evaporates, freeing up dopamine reward pathways.

Suddenly, taking a daily 45-minute walk or getting under a barbell at the gym transitions from an agonizing chore into something rewarding. The medication acts as the initial rescue wedge, but the compounding physical movement is what builds lasting cardiovascular capacity, preserves lean muscle, and protects bone density into late age.

Why the World is Blind to the Shift

If this medical leap is so profoundly positive, why are our systems unready? Because modern society was constructed around sick care, not durability. We built multi-trillion-dollar economic engines designed to manage long, drawn-out chronic illnesses rather than prevent them.

1. The Actuarial Pension Shock: Pension funds, annuity providers, and Social Security models are calculated on existing mortality curves. If a drug eliminates 40% of sudden fatal heart attacks in late middle age and drastically lowers dementia incidence, millions of people will draw retirement benefits for 10 to 20 years longer than calculated.

2. Insurance Business Model Glitches: High upfront drug costs clash with short-term insurance retention. In private health systems, an insurer paying thousands today for a patient’s preventative therapy bears the entire cost, while Medicare reaps the financial savings 20 years later when that patient doesn’t need a kidney transplant or amputation.

3. The Healthcare Infrastructure Pivot: Entire sub-industries dialysis clinics, bariatric surgical centers, and long-term care wards are structured around the downstream consequences of unmanaged metabolic disease. A rapid decline in these conditions requires a seismic retraining and realignment of medical resources.

The Path Forward

We are standing on the edge of a massive demographic divergence. On one side are systems and individuals still clinging to the old paradigm of reactive sick care managing symptoms only after organs fail and limbs are threatened. On the other side is a future where metabolic disease is treated early as a fixable biological dysfunction, granting millions of people clear minds, functional bodies, and pain-free mobility well into their 80s and 90s.

My own three-year trajectory from a 6.6 A1C down to 5.7, from systemic inflammation to painless daily movement is not an isolated anomaly. It is an early preview of what is possible when human biology is freed from metabolic strain.

The medicine to double our collective healthspan has arrived. Now, the rest of the world has to wake up and rebuild its systems to match it.

We are not watching a mere pharmaceutical trend; we are witnessing the birth of the Metabolic Restorative Sector—a fundamental shift from treating sickness after it destroys our bodies to clearing away the biological friction that stops us from living fully. My own journey to better metabolic health is proof of concept. Clean water gave us the 20th century. Metabolic restoration will give us the 21st. The technology is already in our hands, it’s time for the world to wake up, stand up, and start moving.

I am watching 10 little known stocks that stand to cash in big. While Eli Lilly stock is trading near $1200, noted financial expert Joseph Salvani thinks it’s the next Nivdia, but these small stocks could see massive gains as the world discovers what we already know. Join the Insider Advantage find this sector before everyone else does.